

# Preferred Provider Network

- Feb 24, 2021



HONORHEALTH®

COLLABORATING FOR CARE


Innovation Care Partners & HonorHealth – Confidential Information

As of 02/24/2021

## Agenda

- Overview of COVID-19 statistics
- Arizona progress with COVID-19
- Updates from CMS, and Community
- Updates from HonorHealth
- Guest speaker

# Johns Hopkins Tracker




As of 2/24/2021

## CORONAVIRUS STATUS 2/22/2021


- **World** 112 million cases, 2.48 million deaths
- **US** 28.2 million cases, 502k deaths
- **Arizona** 809k cases, 15,502 deaths

### 7 Day Average for Maricopa County

1. Cases # -39.97% (147 per 100k)
2. Deaths # -39.75% (338)
3. % Positivity # -0.28% (8.32)
4. Testing Vol # -9.05%
5. New COVID admits # -29.00% (710)



## ED visits by Syndrome in United States



As of 2/22/21

## Arizona State Report Profile – CDC, 2/14/21

	STATE	FROM PREVIOUS WEEK	FEMA/HHS REGION	UNITED STATES
NEW COVID-19 CASES (RATE PER 100,000)	17,910 (246)	-35%	96,072 (186)	675,717 (204)
VIRAL (RT-PCR) LAB TEST POSITIVITY RATE	9.1%	-3.5%*	6.9%	6.6%
TOTAL VIRAL (RT-PCR) LAB TESTS (TESTS PER 100,000)	176,614** (2,426**)	-18%**	861,551** (1,671**)	8,672,493** (2,612**)
COVID-19 DEATHS (RATE PER 100,000)	886 (12.2)	-4%	4,074 (7.9)	21,457 (6.5)

<https://beta.healthdata.gov/Community/COVID-19-State-Profile-Report-Arizona/iuqv-5x8z>


## Arizona State Report Profile – CDC, 2/14/21

	STATE, % CHANGE					
	STATE	FROM PREVIOUS WEEK	FEMA/HHS REGION	UNITED STATES		
SNFs WITH ≥1 NEW RESIDENT COVID-19 CASE	24%†	-5%*	9%	14%		
SNFs WITH ≥1 NEW STAFF COVID-19 CASE	24%†	-13%*	11%	22%		
SNFs WITH ≥1 NEW RESIDENT COVID-19 DEATH	7%†	-8%*	6%	8%		
NUMBER OF HOSPITALS WITH SUPPLY SHORTAGES (PERCENT)	10 (11%)	+11%	37 (7%)	355 (7%)		
NUMBER OF HOSPITALS WITH STAFF SHORTAGES (PERCENT)	24 (27%)	-8%	150 (28%)	783 (15%)		
COVID-19 VACCINE SUMMARY	DOSES DELIVERED		1ST DOSE ADMINISTERED		2ND DOSE ADMINISTERED	
	TOTAL	RATE PER 100,000	TOTAL	PERCENT OF POPULATION	TOTAL	PERCENT OF POPULATION
	1,393,575	19,145	840,252	11.5%	244,971	3.4%




# Arizona State Report Profile – AZ Hospital Admissions CDC, 2/14/21

## HOSPITAL ADMISSIONS







# COVID-19 Forecasting – AZ, Incident Cases



As of 2/22/21

# Arizona Daily Case Counts

Select a county to filter the epi curve.




# Arizona COVID-19 Deaths

COVID-19 Deaths (total)

15,502


## COVID-19 Deaths by County

Data will not be shown for counties with fewer than three deaths.



## COVID-19 Deaths by Date of Death

**65+: 11,623**



Recent deaths may not be reported yet. Cases missing the date of death are excluded from the graph above, but are included in all other numbers.


Date 2/22/21

# % Positive Diagnostic Tests increasing

As of 2/22/2021

## # tests/day


People tested using All tests by county  
Select a county to filter the data.



People tested using All tests by date of collection



People tested using All Testing by Age Group



■ People tested for COVID-19 and ■ percent positive by week


Percent positive is the number of people with a positive result in Electronic Laboratory Reporting (ELR), out of all people with COVID-19 testing reported via ELR in AZ. Diagnostic tests include PCR

Total % Positive COVID-19 Diagnostic Tests: 14.6%

6%


Total % Positive COVID-19 Serology Tests: 11.4%

44%



Date Updated:


2/22/2021



\*NOTE: Results from the last 4-7 days may not be reported yet.

# ICU Beds in use in Arizona

As of 2/22/2021



## COVID-19 in the 741 Long-Term Care Facilities

Of 7,813 COVID-19 cases among residents, **2,149 (28%)** have been hospitalized and **1,999 (26%)** have died.



Of 5,582 COVID-19 cases among staff, **228 (4%)** have been hospitalized and **14 (0%)** have died.

As of 2/22/2021

# CMS COVID-19 Data Reporting for LTCF

As 2/22/21

## Total Resident COVID-19 Cases and Deaths

TOTAL RESIDENT COVID-19 CONFIRMED CASES

631,427

TOTAL RESIDENT COVID-19 DEATHS

127,235

## Total Staff COVID-19 Cases and Deaths


TOTAL STAFF COVID-19 CONFIRMED CASES

542,443

TOTAL STAFF COVID-19 DEATHS

1,576

## Weekly Resident Cases and Deaths





# VACCINE UPDATES

---



As of 02/24/2021

# COVID-19 Vaccinations in the United States + LTCF

As of 2/22/21

**US**

Total Doses Delivered

75,205,940

Total Doses Administered

64,177,474

Number of People Receiving  
1 or More Doses

44,138,118

Number of People Receiving  
2 Doses

19,438,495

**LTCF**

Total Number of Doses Administered  
in Long-Term Care Facilities

6,579,236

Number of People with 1 or More  
Doses in Long-Term Care Facilities

4,449,465

Number of People with 2 Doses in  
Long-Term Care  
Facilities

2,096,808

**AZ  
LTCF**

## Arizona

Total LTC Doses Administered: 85,333

People in LTC with 1+ Doses: 69,168

People in LTC with 2 Doses: 15,938

## AZ Vaccines Administered

### Arizona

20.70


doses given per 100 people

15.2%

of population got at least 1 shot


5.4%

are fully vaccinated



As of 2/22/2021

## AZ Vaccines Administered



**Arizona**, the latest vaccination rate is **41,349 doses/day**, on average.

At this rate, it will take **an estimated 7 months** to cover **75%** of the population with a two-dose vaccine

*As of 2/22/2021*


## AZ Vaccines Administered

People who have received at least one dose  
by **race/ethnicity**



White	527,801 (49.0%)
Other Race/Unknown	386,504 (35.9%)
Hispanic or Latino	86,242 (8.0%)
American Indian or Alaska Native	33,642 (3.1%)
Asian	24,436 (2.3%)
Black or African American	16,105 (1.5%)
Native Hawaiian or Other Pacific Islander	2,453 (0.2%)

People who have received at least one  
dose by **age and gender** (■ male ■ female)



As of 2/22/2021


# Inequities in Vaccine Distribution

**Fig. 1: Half of the world's supply has been reserved for just 15% of its population**

FEB 13TH 2021

## Covid-19 vaccine orders

At February 10th 2021, countries sized by population in 2018.



\*Aged 15 and over †Assuming Chinese vaccine makers distribute their spare capacity locally ‡Assuming two Sputnik V doses are available for every adult §Counting half of Serum Institute output saved for local use






Source: Economist

As of 2/15/2021

# Operation Warp Speed EUA Tracker

As of 2/16/2021

Fig. 2: Operation Warp Speed EUA Tracker

Developer	Vaccine Candidate	Pre-Clinical	Phase 1	Phase 2	Phase 3	EUA Approval	Phase 3 Trial Results	Doses	Storage Requirement
J&J	JNJ-78436735	P1 Data Readout - Jan 13'21 (Positive)			P3 Trial Start Sept 3'20	Expected Mid-Feb'21 <b>Feb 26th</b>	66% *Phase 3 trial results from across eight countries and 44k+ volunteers		Standard Cold Chain
Astra Zeneca/Oxford	AZD1222	P1 Data Readout - Dec 8'20 (Flagged)			P3 Trial Start Aug 31'20	Delayed to March/Apr'21 <b>March/April</b>			Standard Cold Chain
Novavax	NVX-CoV2373	P1 Data Readout - March'21			P3 Trial Start Dec 28'20	Expected Apr-May'21 <b>April/May</b>			Standard Cold Chain
Sanofi Pasteur/GSK	SARS-CoV-2 Vaccine			P1/2 Trial Start Sept 3'20	Delayed to end of '21	<b>End '21</b>			Standard Cold Chain
Merck	V591		P1 Trial Start Sept'20		Discontinued 1/25/2021				Ultra Cold Chain

Source: Nephron Research analysis of data from the World Health Organization, Regulatory Affairs Professionals Society, STAT News, and company releases.



## Vaccine Side Effects – mirror clinical trials

Local and systemic reactions, day 0-7*,†	All vaccines %	Pfizer- BioNTech dose 1 %	Pfizer-BioNtech dose 2 %	Moderna dose 1 %
Pain	70.7	67.7	74.8	70.1
Fatigue	33.4	28.6	50.0	29.7
Headache	29.4	25.6	41.9	26.0
Myalgia	22.8	17.2	41.6	19.6
Chills	11.5	7.0	26.7	9.3
Fever	11.4	7.4	25.2	9.1
Swelling	11.0	6.8	26.7	13.4
Joint pain	10.4	7.1	21.2	8.6
Nausea	8.9	7.0	13.9	7.7

# IN THE NEWS

---

As of 02/24/2021

## High-Dose Zinc and Ascorbic Acid Supplementation

- Do high-dose zinc, high-dose ascorbic acid, and/or a combination of the 2 reduce the duration of symptoms of SARS-CoV-2 ?
- 214 patients with confirmed SARS-CoV-2 infection
- April 27, 2020, to October 14, 2020
- Patients were randomized in a 1:1:1:1 allocation ratio to receive either 10 days of zinc gluconate (50 mg), ascorbic acid (8000 mg), both agents, or standard of care.

## High-Dose Zinc and Ascorbic Acid Supplementation

- **Outcomes:**

- 1° end point - reach 50% reduction in symptoms (severity of fever, cough, shortness of breath, and fatigue)
- 2° end points - days required to reach symptom severity score of 0, cumulative severity score at day 5, hospitalizations, deaths, adjunctive prescribed medications, and adverse effects

- **Results**

- No significant difference among the 4 groups for the primary and secondary end point.


## Variants of the Virus that Causes COVID-19

- Viruses constantly change through mutation, and new variants of a virus are expected to occur over time
- Multiple variants of the virus that causes COVID-19 are circulating globally:
  - United Kingdom, B.1.1.7 variant: spreads more easily and quickly than other variants. First seen in the US at the end of December 2020
  - South Africa, B.1.351 variant: emerged independently of B.1.1.7. Shares some mutations with B.1.1.7. First seen in US at the end of January 2021
  - Brazil, P.1 variant: this variant contains a set of additional mutations that may affect its ability to be recognized by antibodies. First seen in US at the end of January 2021.

## Variants of the Virus that Causes COVID-19

Variant	Reported Cases in US	Number of States Reporting
B.1.1.7	1661	44
B.1.351	22	10
P.1	5	4

Emerging Variant Cases in the United States\*†




**Arizona**  
 B.1.1.7 Variant : 6  
 P.1 Variant : 0  
 B.1.351 Variant : 0

As of 2/21/21

Territories
 AS
GU
MH
FM
MP
PW
PR
VI

## Germany's Contagion



- Germany's contagion rate rose to the highest level in more than a week
- Amid concerns about fast-spreading variants, Germany imposed border controls with the Czech Republic and Austria'



As of 2/23/2021

## More variants on the rise




Figure 1.

[Download figure](#) | [Open in new tab](#)

**Rising prevalence of SARS-CoV-2 S:Q677P and Q677H variants in the United States.**

(A) Monthly number of Q677H and Q677P variant viruses in the USA and worldwide found in GISAID data. Note that data for samples collected in December and January is incomplete for many surveillance facilities. (B) State by state prevalence of United States Q677H and Q677P variant frequency (out of total GISAID data up to Feb 03, 2021). A full table of acknowledgements for the data included in this analysis is available in the supplement.

Q677H and Q677P variants with lower ability to neutralize antibodies

U.K. scientists - suggests that the B.1.1.7 Covid-19 variant may be between 30% and 70% deadlier than the original SARS-CoV-2 virus

<https://www.medrxiv.org/content/10.1101/2021.02.12.21251658v1.full-text>

## All-in-One Covid Vaccine could tackle variants

- US announced last week agreement with CureVac NV to study variants, pairing artificial intelligence to predict future mutations with mRNA technology to rapidly produce new vaccines
- GlaxoSmithKline Plc is working with CureVac
- Pfizer, Moderna and J&J are working on developing booster vaccines
- AstraZeneca and Oxford will have a tweaked version available this fall

<https://www.bloomberg.com/news/articles/2021-02-13/rise-of-variants-sparks-push-for-all-in-one-covid-vaccines?srnd=premium>

## Pfizer-BioNTech Shot Stops Covid Spread

- **Israeli Study:**
- The [Pfizer Inc.](#) and [BioNTech SE](#) Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected
- First real-world indication that the immunization will curb transmission of the coronavirus
- Immunization was 89.4% effective at preventing laboratory-confirmed infections
- Israeli authorities said the Pfizer-BioNTech shot was 99% effective at preventing death from the virus

## Pfizer-BioNTech Shot Stops Covid Spread

- Indicate the vaccine may also prevent asymptomatic carriers from spreading the virus that causes Covid-19
- Encouraging data to support immunization for achieving Herd Immunity
- Study wasn't designed to accurately measure a reduction in transmission of SARS-CoV-2

<https://www.bloomberg.com/news/articles/2021-02-21/pfizer-biontech-shot-stops-covid-s-spread-israeli-study-shows>

# Pfizer-BioNTech Shot Stops Covid Spread


	Unvaccinated	Vaccinated	
		1–14 days after first dose	15–28 days after first dose
All SARS-CoV-2 positive			
Number of cases	89	55	26
Number of exposure days	120 575	100 433	88 126
Rate per 10 000 person-days	7.4	5.5	3.0
Rate reduction compared with unvaccinated (95% CI)	..	26% (–4 to 47)	60% (38 to 74)
Adjusted rate reduction compared with unvaccinated (95% CI)*	..	30% (2 to 50)	75% (72 to 84)
Symptomatic COVID-19			
Number of cases	60	28	11
Number of exposure days	120 575	100 433	88 126
Rate per 10 000 person-days	5.0	2.8	1.2
Rate reduction compared with unvaccinated (95% CI)	..	44% (12 to 64)	75% (52 to 87)
Adjusted rate reduction compared with unvaccinated (95% CI)*	..	47% (17 to 66)	85% (71 to 92)

SARS-CoV-2 positivity was determined by PCR. \*Rate ratios of new cases in vaccinated compared with unvaccinated health-care workers each day were adjusted for community exposure rates using Poisson regression (appendix). The adjusted estimates were subtracted from 1 to obtain rate reductions.

<https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900448-7>

## Daily COVID-19 Vaccinations

Estimated Average Daily Doses Administered in the United States: Current and Projected



NOTES: Doses represent combined number of doses of both the Pfizer and Moderna vaccines. February 15 is the average daily rate based on a 7-day rolling average as provided by the Bloomberg Vaccine Tracker. March 31 is an estimate based on the projected delivery schedule of manufacturers. It represents the average daily number of remaining doses to be delivered between February 15 and March 31, assuming the production schedule is met.

SOURCES: KFF analysis of data from CDC, Bloomberg, Pfizer, Moderna.

KFF

Pace of vaccination has begun to pick up across the country

Average of **1.33 million doses per day** were administered.

US purchased Vax 600 mil of doses

## Covid-19: Pfizer/BioNTech Vaccine Update

- February 19, 2021 — Pfizer/BioNTech announced the submission of new data to the FDA demonstrating vaccine stability stored at -25 C to -15C (-13 F to 5 F)
  - temperatures common in pharmaceutical freezers and refrigerators.
- **Trial in pregnant women**
  - Randomized, placebo-controlled, observer-blind study in approximately 4,000 healthy pregnant women 18 years of age or older vaccinated during 24 to 34 weeks of gestation
  - Participate in the study for approximately 7 to 10 months
  - Assess safety in infants of vaccinated pregnant women, transfer of potentially protective antibody to their infants (till 6 months of age)



## Liability protections from COVID-related suits

- Indiana Gov. Eric Holcomb (R) on Thursday signed a proposal that gives businesses, including SNF, civil immunity from coronavirus-related lawsuits
- Proponents argued that the legislation would protect businesses and providers from frivolous lawsuits as they adapted during the pandemic
- More than 20 states that have enacted liability protections for nursing homes during the public health crisis
- “Our healthcare heroes are deserving of the liability protections....” FHCA Executive Director Emmett Reed

## CDC Report on Vaccine Safety 2/19/21

- CDC released vaccine safety data reported by healthcare providers during the first month of vaccinations (Dec. 14, 2020, through Jan. 13, 2021)
- Approximately 1 million LCTF residents were vaccinated during that period.
  - 150 reports (3 out of every 2,000 participants) of adverse events, ranging from serious to non-serious
  - 78 deaths (fewer than 1 out of every 12,000 participants) reported

## CDC Report on Vaccine Safety 2/19/21

- About 13.7 mill vaccine doses were given during the study
- Roughly 7,000 reports of adverse events (a little more than 1 out of every 2,000)
  - Fewer than 650 of those were classified as serious - headache, fatigue, and dizziness.
  - A total of 113 deaths reported (1 out of every 125,000 participants)
- Per CDC - deaths among residents was c/w expected all-cause mortality among the group and did not “indicate any unexpected pattern that might suggest a causal relationship with vaccination.”


[https://www.cdc.gov/mmwr/volumes/70/wr/mm7008e3.htm?s\\_cid=mm7008e3\\_w](https://www.cdc.gov/mmwr/volumes/70/wr/mm7008e3.htm?s_cid=mm7008e3_w)

# Deadliest Jobs of 2020

## The Scientific American analysis:

- Exact toll of COVID-19 on nursing home residents and staff members is uncertain due to incomplete data
- Per CDC – only 37.5% of staff agreed to obtain vaccination during the first month.
- Concerns for “sense of distrust among overworked and underpaid staffs that have gone through an incredibly difficult year.”

<https://www.scientificamerican.com/article/nursing-home-workers-had-one-of-the-deadliest-jobs-of-2020/>



## Vaccines Mandatory For Staff

- Atria Senior Living, a leading operator of senior living communities across the United States and Canada
  - More than 185 locations in 26 states and seven Canadian provinces.
  - Over 19,000 residents and 10,000 U.S. employees
- Company has made the decision to make the vaccine a mandatory condition of employment
  - "the responsible thing to do in light of the threat posed by COVID-19 and the hope the vaccine holds in eliminating that threat to our residents and staff, as well as society at large."

<https://www.prnewswire.com/news-releases/atria-senior-living-makes-covid-19-vaccines-mandatory-for-staff-301205329.html>

## Who

Patients experiencing acute or chronic COVID-19 symptoms and related complications in any setting such as clinics, home healthcare, long term care, assisted living and hospitals.

## What

A referral source for healthcare providers to help their patients navigate through the complexities of COVID-19 related serious illness.

## Cost

There is no fee to participate in this program.

## More information

Visit our website: [palliative.vsee.me/u/clinic](https://palliative.vsee.me/u/clinic), complete the intake form, attach a medical history form (if applicable), and work with the patient to schedule an appointment. Questions may be directed to [sseversone@azhha.org](mailto:sseversone@azhha.org) or 602-445-4303.



**Palliative care is focused on helping patients live well as long as they can.**

We work with the existing healthcare team to provide an extra layer of support and care focused on aligning patients' values and goals with available treatment options.

Do you have a patient in your care who is experiencing acute or chronic COVID-19 symptoms and related complications and would benefit from a telehealth consultation with a Palliative Care provider? This Arizona-based program helps healthcare providers connect patients to a licensed and credentialed palliative care provider. Palliative care provides expert communication for patients and families to achieve goal-concordant care while addressing the symptoms of their serious illness.



## AzHHA Palliative Care

Telehealth service offered at **NO COST**

Help patients live with quality and as long as they can

# MONOCLONAL ANTIBODY TREATMENTS

---

## New EUA Etesevimab + Bamlanivimab combo

- FDA gave EUA on 2/9 for combination monoclonal antibody tx
- For non-hospitalized COVID-19 patients at high risk of developing complications age 12 and older
- Randomized, double-blind, placebo-controlled clinical trial enrolled 1,035 non-hospitalized adults with mild to moderate symptoms at high risk
  - 36 (7%) with placebo were hospitalized or died vs. 11 (2%) in the treatment group (70% reduction)
  - 10 deaths, all in placebo
  - participants had a greater and more rapid virus level decline than those who received placebo

<https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0>



## HonorHealth Monoclonal Antibody Process

### Identify

- Provider identifies patient that meets criteria for monoclonal antibody treatment

### Call

- Call COVID Infusion Line **480-587-7020** to refer patient
- Mon-Fri 8a-5p, 9a-1p weekends
- **Currently at Shea, Osborn, JCL, Sonoran Crossing**

### Referral

- Nurse to review patient criteria, if meets criteria then patient will be referred to the closest HH ED

**Please make sure your patient meets criteria BEFORE calling the COVID Infusion Line!**

# HonorHealth Monoclonal Ab Criteria

## INCLUSION CRITERIA

- Age  $\geq 18$  years
- **First** COVID-19 positive test collected within 72 hours of monoclonal antibody infusion
- Mild to Moderate COVID-19 disease with one or more of the following symptoms within 10 days of symptom onset:
  - Fever ( $t_{max} > 101.4$ ), cough, sore throat, malaise, headache, muscle pain, shortness of breath, GI symptoms
- **At risk for severe illness (must meet 1 or more of the following criteria):**
  - Age  $\geq 65$
  - Underlying medical condition
    - Obesity ( $BMI \geq 35$ )
    - Diabetes
    - Immunocompromised state and/or receiving immunosuppressive treatment
    - Chronic kidney disease
  - Age  $\geq 55$  and have one or more of the following
    - Cardiovascular disease, or hypertension, or COPD/other chronic respiratory disease

## EXCLUSION CRITERIA

- Any hospitalized patient
- Requiring supplemental oxygen secondary to COVID-19 or require an increase in baseline oxygen flow rate due to COVID-19.
- Hemodynamic instability
- Suspected or proven serious bacterial, fungal, viral, or other infection
- History of previous positive SARS-CoV-2 serology test
- Any co-morbidity requiring surgery within  $< 7$  days or considered life-threatening within 30 days
- Pregnant or breastfeeding women
- Pediatric
  - Age  $< 18$  years

## AZ COVID-19 Hotline for monoclonal Ab

*For patients who meet criteria, providers can contact the COVID-19 Hotline (administered by Arizona Poison and Drug Information Systems) to determine the closest healthcare facility location that has received an allocation of Bamlanivimab and Casirivimab/Imdevimab (Regeneron):*

**844-542-8201**

- Same criteria as HH except they **allow age 12-17 years** AND have one or more of the following:
  - BMI >85<sup>th</sup> percentile for age and gender
  - Sickle cell disease
  - Congenital or acquired heart disease
  - Neurodevelopmental disorders; for example, cerebral palsy
  - A medical-related technological dependence; for example, tracheostomy, gastrostomy, vent
  - Asthma, reactive airway, or other chronic respiratory disease that requires daily medication for control

# **PUBLIC HEALTH UPDATES**

---

As of 02/24/2021

## CDC Quarantine Guidance Update

Vaccinated persons with an exposure to someone with suspected or confirmed COVID-19 are **NOT** required to quarantine if they meet all of the following criteria:

- Are fully vaccinated (i.e.,  $\geq 2$  weeks following receipt of the second dose in a 2-dose series, or  $\geq 2$  weeks following receipt of one dose of a single-dose vaccine)
- Are within 3 months following receipt of the last dose in the series
- Have remained asymptomatic since the current COVID-19 exposure

Persons who do not meet all 3 of the above criteria should continue to follow current quarantine guidance after exposure to someone with suspected or confirmed COVID-19.

*As of 2/23/2021*

## Quarantine Guidance Update

- **Exception:** Vaccinated inpatients/residents in **healthcare and correctional settings** (i.e., hospitals, hospice, skilled nursing facilities, jail/prison) should continue to quarantine for 14 days following their last exposure to a person with COVID-19. This is due to the higher risk of severe disease and death in these populations and challenges with social distancing in these settings.
- **Exception:** Outbreaks with variant COVID-19 strains are also exceptions to this policy in consultation with Public Health.


*As of 2/23/2021*

## Public Health Recommendations for Vaccinated Persons

- Protection from vaccine is not immediate; vaccine is a 2-dose series and will take 1 to 2 weeks following the second dose to be considered fully vaccinated
- No vaccine is 100% effective
- Given the currently limited information on how well the vaccine works in the general population; how much it may reduce disease, severity, or transmission; and how long protection lasts, vaccinated persons should continue to follow all [current guidance](#) to protect themselves and others, including:
  - Wearing a mask
  - Staying at least 6 feet away from others
  - Avoiding crowds
  - Washing hands often
  - Following [CDC travel guidance](#)
  - ~~– Following quarantine guidance after an exposure to someone with COVID-19~~
  - Following any applicable workplace or school guidance




## Expanded Phase 1B






## Maricopa Stats

- Almost 530K (over 15%) of Maricopa County residents have been vaccinated
- More than 180K or 1 in 3 have received 2 doses
- Half of those vaccinated are 65 and older
- 53% of those who are 75 and older in Maricopa County have been vaccinated



As of 2/23/2021

## Vaccination Sites Expanding



<https://www.maricopa.gov/5659/COVID-19-Vaccine-Locations>

## Maricopa County POD Sites

Region	Host	Address	Populations Served	Appointments
Central	Banner Health	1826 W. McDowell Rd, Phoenix (Arizona State Fairgrounds)	Healthcare workers and Adults 65+	Required; limited availability
Northwest	Banner Health	14300 W. Granite Valley Dr., Sun City	Healthcare workers and Adults 65+	Required; limited availability
Northeast	HonorHealth	2500 W. Utopia Dr., Phoenix	Healthcare workers and Adults 65+	Required; no availability
Southeast	Dignity Health	2626 E. Pecos Rd., Chandler	Healthcare workers, K-12 staff, childcare workers, law enforcement, 65+	Required; limited availability
Southwest	Abrazo	13677 W. McDowell Rd., Goodyear	Healthcare workers, K-12 staff, childcare workers, law enforcement, 65+	Required; limited availability
Central	Grand Canyon University	5115 N. 27th Ave., Phoenix (this is a walk-through location)	Healthcare workers, K-12 staff, childcare workers, law enforcement, 65+	Required; limited availability

Manufacturer	Location	Address	City	Registration Link
Moderna	Adelante Healthcare Peoria	15525 N 83rd Ave, Peoria, AZ 85382	Peoria	<a href="#">Check appointments</a>
Moderna	Albertsons #1971	8950 W Bell Rd, Peoria, AZ 85382	Peoria	<a href="#">Check appointments</a>
Moderna	Albertsons # 0991	8240 W Deer Valley Rd, Peoria, AZ 85382	Peoria	<a href="#">Check appointments</a>

## Vaccine Sites

- MCDPH Regional PODs used in Phase 1a
  - Banner Fairgrounds (Central)
  - Honor Corporate (NE)
  - Banner Del Web (NW)
  - Abrazo West (SW)
  - Dignity - Chandler Gilbert College (SE)
  - Grand Canyon University
  - Midwestern University
- Arizona PODs: State Farm Stadium, Phx Municipal Stadium
- Retail Pharmacy – Planning on-site vaccination and events
- School PODs continue with new school districts hosting events every week
  - School Districts have private registrations managed by their pharmacy partners
- FQHC, other private providers registered as COVID-19 vaccinators
- [Maricopa County Vaccine Finder](#)

<https://www.maricopa.gov/5659/COVID-19-Vaccine-Locations>



## Covid-19 Vaccine Registration

- <https://www.maricopa.gov/5651/Phase-1B>
- Prioritized groups include
  - **Adults age 65 and older**
  - Adults living in congregate settings
  - K-12 Education and Childcare providers
  - Law Enforcement/Protective Services – sworn officers
  - 1a eligible individuals can continue to receive 1<sup>st</sup> and 2<sup>nd</sup> doses
- NO MCDPH PRE-SCREENING
- Screening for eligibility via site registration

# HONORHEALTH UPDATES

---

As of 02/24/2021

## HonorHealth

- Visitation is now on “concerned” vs. restricted. Patients are allowed to have a visitor during certain hours.
- Still no liaisons allowed in.



# GUEST SPEAKER

---





## Sepsis Management: Skilled Nursing Setting

Madhu Murthy Board Certified Infectious Disease MD & CMO  
&  
Andi Ravenscroft LNHA, Growth & Strategy Executive



## Who are Nod Specialists?

A specialty practice designed to provide comprehensive specialist services through simple and easy to use technology.

### Easy and timely access to quality care by specialists

- Consistent weekly rounding
- 24/7 on-demand access
- In-person or telemedicine rounding options
- Covered 100% by insurance; zero cost to the facility


Specialties Available: Infectious Disease, Endocrinology, Nephrology, and Behavioral Health

Currently supporting over 25 skilled nursing facilities.

# Today's Focus: Managing Sepsis in Your Facility

- Sepsis is avoidable but still the #1 most expensive readmission.
- Sepsis is the primary cause of death from infection.
- For nearly 80% of patients, sepsis begins outside of the hospital.
- The average length of stay in a hospital is 11 days.
- On average, sepsis causes a loss of \$6,325 in revenue per patient day in a skilled nursing facility when transferred to the hospital for treatment.

# How to Manage Sepsis in Your Facility with Infectious Disease Experts




## Case Study: Impacts of Treating Sepsis In Place

**88%** of Sepsis Patients Successfully Treated In-Place With No Transfers Needed.

**50%**  
Reduction in  
Readmissions

**\$75,900**  
Saved On Lost  
Patient Days



## COVID-19 Vaccination Update

- Significant reduction in case rates
- Reduction in hospitalizations
- Reduction in case fatality
- Efficacy against emerging variants:
  - B.1.1.7 (UK)
  - B.1.351 (South Africa)
  - P.1. (Brazil)
- mRNA vaccine flexibility and adaptability
- More data needed

## Summary

- Know signs/symptoms of sepsis
- Early detection will save lives
- Antibiotic management is everyone's responsibility
- Telehealth tools to improve access to care
- Quality patient outcomes
- Reduced healthcare costs
- Higher rates of COVID-19 vaccination

## Questions & Answers Session

Thank you!

**To learn more, contact:**

Andi Ravenscroft

480-825-4005

aravenscroft@nodmd





## Questions – Type in Q & A Section

**Post-Acute Website:** <https://innovationcarepartners.com/postacutecommunications>



- If you have further questions or issues you would like to discuss
- Please contact:  
Francisco Gonzalez– Preferred  
Network & Clinical Development  
Supervisor  
[fgonzalez@icphealth.com](mailto:fgonzalez@icphealth.com)